Mortality and PFS in antifibrotic and control groups for patients with 6, 12 and 18 months of follow-up
| Antifibrotic (n=104) | Control (n=64) | P value | |
| 6-month mortality (%) | 13 (12.5) | 13 (20.3) | 0.174 |
| 12-month mortality (%) | 27 (26.0) | 22 (34.4) | 0.244 |
| 18-month mortality (%) | 34 (34.0)* | 28 (44.4)† | 0.181 |
| PFS of 6 months (%) | 78 (75.0) | 36 (56.3) | 0.012 |
| PFS of 12 months (%) | 53 (51.0) | 22 (34.4) | 0.036 |
| PFS of 18 months (%) | 37 (37.0)* | 16 (25.4)† | 0.124 |
*n=100 for antifibrotic-treated patients with 18-month follow up.
†n=63 for control patients with 18-month follow up.
PFS, progression-free survival.